SERM ranks best in reducing risk of cancer and CVD; however, it causes high incidence of death (PTH (77.3%) > SERM (72.4%) > placebo (47.2%) > BP (37.6%) > mAb (15.5%)) among the available interventions evaluated. Here, PTH is linked to cancer.